Your browser doesn't support javascript.
loading
Are ketogenic diets promising for Alzheimer's disease? A translational review.
Lilamand, Matthieu; Porte, Baptiste; Cognat, Emmanuel; Hugon, Jacques; Mouton-Liger, François; Paquet, Claire.
Affiliation
  • Lilamand M; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France. mlilamand@hotmail.fr.
  • Porte B; Centre de Neurologie Cognitive/CMRR Paris Nord Ile de France, APHP Nord Université de Paris, Lariboisière Hospital 200, rue du Faubourg Saint Denis, 75010, Paris, France. mlilamand@hotmail.fr.
  • Cognat E; Department of Geriatrics, Bichat and Bretonneau Hospitals, APHP Nord Université de Paris, 75018, Paris, France. mlilamand@hotmail.fr.
  • Hugon J; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France.
  • Mouton-Liger F; Centre de Neurologie Cognitive/CMRR Paris Nord Ile de France, APHP Nord Université de Paris, Lariboisière Hospital 200, rue du Faubourg Saint Denis, 75010, Paris, France.
  • Paquet C; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France.
Alzheimers Res Ther ; 12(1): 42, 2020 04 14.
Article in En | MEDLINE | ID: mdl-32290868
BACKGROUND: Brain amyloid deposition and neurofibrillary tangles in Alzheimer's disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans. MAIN BODY: We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis. CONCLUSION: The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Diet, Ketogenic / Alzheimer Disease / Cognitive Dysfunction Type of study: Systematic_reviews Limits: Adult / Animals / Humans / Male Language: En Journal: Alzheimers Res Ther Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Diet, Ketogenic / Alzheimer Disease / Cognitive Dysfunction Type of study: Systematic_reviews Limits: Adult / Animals / Humans / Male Language: En Journal: Alzheimers Res Ther Year: 2020 Document type: Article